The costs of allergy and asthma and the potential benefit of prevention strategies

Chemical Immunology and Allergy

Volumn 84, Issue , 2004, Pages 184-192

  Weiss, Kevin ^a,b,f   Haus, Matthias ^c,d   Iikura, Yoji ^e  

^a Midwest Center for Health Services and Policy Research   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d ASTRAZENECA   (United Kingdom)

^e SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Center for Pain Studies   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ALLERGY; ASTHMA; CHILD; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 6044267151     PISSN: 16602242     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000081611     Document Type: Review

References (49)

1. Weiss KB, Sullivan SD: The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3-8. (NC)
2. Asthma Programme in Finland 1994-2004. Clin Exp Allergy 1996;26(suppl 1):1-24. (III)
3. Australian Bureau of Statistics: 1989/1990 National Health Survey: Asthma and other Respiratory Conditions. Australian cat No 4373.0, 1991. (III)
4. Donnelly JE, Donnelly WJ, Thong YH: Parental perception and attitudes toward asthma and its treatment: A controlled study. Soc Sci Med 1987;24:431-437. (III)
5. Wasilewski Y, Clark N, Evans D, Feldman CH, Kaplan D, Rips J, Mellins RB: The effect of paternal social support on maternal disruption caused by childhood asthma. J Community Health 1988;13:33-42. (III)
6. Vance VJ, Taylor WR: The financial costs of chronic childhood asthma. Ann Allergy 1971;29: 455-460. (III)
7. Law AW, Reed SD, Sundy JS, Schulman KA: Direct costs of allergic rhinitis in the United States: Estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003;111: 296-300. (III)
8. Storms WL, Meltzer EO, Nathan RA, Seiner JC: The economic impact of allergic rhinitis. J Allergy Clin Immunol 1997;99:S280-S284. (III)
9. Gupta R, Sheikh A, Strachan DP, Anderson HR: Burden of allergic disease in the UK: Secondary analyses of national databases. Clin Exp Allergy 2004;34:520-526. (III)
10. Weiss KB, Gergen PJ, Hodgson TA: An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862-866. (III)
11. Mellis CM, Peat JK, Bauman AE, Woolcock AJ: The costs of asthma in New South Wales. Med J Aust 1991;155:522-528. (III)
12. Clark THJ: Action Asthma. The Occurrence and Costs of Asthma. Cambridge, Cambridge Medical Publications, 1990. (NC)
13. Thompson S: On the social cost of asthma. Eur J Respir Dis Suppl 1984;136:185-191. (III)
14. National Asthma Campaign: Report on the Cost of Asthma in Australia. National Asthma Council Australia, South Melbourn, 1993. (III)
15. Krahn MD, Berka C, Langlois P, Detsky AS: Direct and indirect costs of asthma in Canada, 1990. Can Med Assoc J 1996;154:821-831. (III)
16. Rutten-van Molken MP, Postma MJ, Joore MA, Van Genugten ML, Leidl R, Jager JC: Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999;93:779-787. (III)
17. Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: Direct and indirect costs in Switzerland. Eur Respir J 1999;13:281-286. (III)
18. Chew FT, Goh DY, Lee BW: The economic costs of asthma in Singapore. Aust NZ J Med 1999;29:228-233. (III)
19. Global Initiative for Asthma; chapter 8: Socioeconomics. Publication 95-3659. Bethesda, National Institutes of Health, National Heart, Lung, and Blood Institute, 1995. (NC)
20. Galvan MC, Castillo JC, Llano EM, Duque DS: Un estudio economico sobre asma en Mexico. Rev Alerg Mex 2000;3:96-99. (III)
21. Lal A, Kumar L, Malhortra S: Socio-economic burden of childhood asthma. Indian Pediatr 1994; 31:425-432. (NC)
22. Weiss KB, Sullivan SD, Lyttle CS: Trends in the costs of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol 2000;106:493-499. (III)
23. Jacobson L, Hertzman P, Lofdahl CG, Skoogh BE, Lindgren B: The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991. Respir Med 2000;94:247-255. (III)
24. Haahtela T, Klaukka T, Koskela K, Erhola M, Laitinen LA: Asthma programme in Finland: A community problem needs community solutions. Thorax 2001;56:806-814. (III)
25. McMenamin P: Cost of hay fever in the United States in 1990. Ann Allergy 1994;73:35-39. (III)
26. Reed SD, Lee TA, McCrory DC: The economic burden of allergic rhinitis. Pharmacoeconomics 2004;22:345-361. (NC)
27. Donahue JG, Greineder DK, Connor-Lacke L, Canning CF, Platt R: Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 1999;82: 339-347. (III)
28. Lozano P, Sullivan SD, Smith DH, Weiss KB: The economic burden of asthma in US children: Estimates from the National Medical Expenditure Survey. J Allergy Clin Immunol 1999;104: 957-963. (III)
29. Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG: Allergic rhinitis in Rochester, Minnesota, residents with asthma: Frequency and impact on health care charges. J Allergy Clin Immunol 1999;103:54-59. (III)
30. Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D: Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 2003;21: 116-122. (III)
31. Blaiss MS: Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 2000; 21:7-13. (III)
32. Blanc PD, Trupin L, Eisner M, Earnest G, Katz PP, Israel L, Yelin EH: The work impact of asthma and rhinitis: Findings from a population-based survey. J Clin Epidemiol 2001;54:610-618. (III)
33. Ray NR, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M, et al: Medical expenditures for the treatment of allergic rhinoconjunctivitis in the United States in 1996 including the contributions of related airway illness. J Allergy Clin Immunol 1999;103:401-407. (III)
34. Liao E, Leahy M, Cummins G: The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: An updated analysis. Am J Manag Care 2001;7:S459-S468. (III)
35. Okuda M: Cost implication of allergic rhinitis. Allergy Immunol 1998;5:86-91. (III)
36. Lodha R, Puranik M, Kattal N, Kabra SK: Social and economic impact of childhood asthma. Indian Pediatr 2003;40:874-879. (III)
37. Drummond MF, O'Brien B, Stoddart GL, Torrance GW: Methods for the Economic Evaluation of Health Care Programmes, ed 2. New York, Oxford University Press, 1987. (NC)
38. Banta HD, Luce BR: Health Care Technology and Its Assessment. New York, Oxford University Press, 1993. (NC)
39. Russell LB, Siegel JE, Daniels N, Gold MR, Luce BR, Mandelblatt JS: Cost-effectiveness analysis as a guide to resource allocation in health: Roles and limitations; in Gold MR, Siegel JE, Russell LB, Weinstein MC (eds): Cost-Effectiveness in Health and Medicine. New York, Oxford University Press, 1996, chap 1, pp 3-21. (NC)
40. Sullivan SD, Weiss KB. Health economics of asthma and rhinitis. Part II. Assessing the value of interventions. J Allergy Clin Immunol 2001;107:203-210. (III)
41. Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, Pauwels RA, Weiss KB: Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003;112:1229-1236. (II)
42. Clearing the Air: Asthma and Indoor Air Exposures. Committee on the Assessment of Asthma and Indoor Air, Division of Health Promotion and Disease Prevention. Washington, Institute of Medicine, 2000. (NC)
43. Elixhauser A, Leidy NK, Halpern MT: Cost and outcome implications for prevention; in Weiss KB, Buist AS, Sullivan SD (eds): Asthma's Impact on Society: The Social and Economic Burden. Lung Biology in Health and Disease. New York, Dekker, 1999, vol 138, pp 291-311. (NC)
44. Sullivan SD, Weiss KB: Assessing cost-effectiveness in asthma care: Building an economic model to study the impact of alternative intervention strategies. Allergy 1993;47:146-152. (NC)
45. Centers for Disease Control and Prevention: Assessing the effectiveness of disease and injury prevention programs: Costs and consequences. MMWR Recomm Rep 1995;44(RR-10):1-10. (NC)
46. Sullivan SD, Buxton M, Andersson LF, Lamm CJ, Liljas B, Chen YZ, Pauwels RA, Weiss KB: Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003;112:1229-1236.
47. Lahdensuo A, Haahtela T, Herrala J, Kava T, Kiviranta K, Kuusisto P, Pekurinen M, Peramaki E, Saarelainen S, Svahn T, Liljas B: Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ 1998;316:1138-1139. (II)
48. Liljas B, Lahdensuo A: Is asthma self-management cost-effective (review)? Patient Educ Couns 1997;32:S97-S104. (NC)
49. Paltiel AD, Fuhlbrigge AL, Kitch BT, Liljas B, Weiss ST, Neumann PJ, Kuntz KM: Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: Results from the asthma policy model. J Allergy Clin Immunol 2001:108:39-49. (NC)